291 patents currently held
111 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Apr 2027. from the record
Of the 111 now held by other companies, 64 name Bristol Myers Squibb Company as their current owner, and 47 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
42
Ending by 2030
Apr 2027
Next term end
140
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2031 · High confidence
Also notable
Ends Apr 2027 · High confidence
Also notable
Ends Jun 2030 · High confidence
Also notable
Ends Dec 2033 · High confidence
Also notable
Ends Oct 2034 · High confidence
Also notable
Ends Sep 2033 · High confidence
Also notable
Ends Nov 2027 · High confidence
Also notable
Ends Jun 2031 · High confidence
Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same
US 8,518,972
The most cited patent in this portfolio, cited by 121 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2031.
Polymorphic Forms of 3-(4-Amino-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-Dione
US 7,465,800
Cited by 78 later US patents, top 10% of utility patents granted in 2008 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Oral Formulations of Cytidine Analogs and Methods of Use Thereof
US 8,846,628
Cited by 52 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Histone Demethylase Inhibitors
US 8,952,151
Cited by 45 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Bromodomain Inhibitors
US 9,034,900
Cited by 38 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2034.
Salts and Solid Forms of (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-Oxoisoindolin-2-YL)PIPERIDINE-2,6-Dione and Compositions Comprising and Methods of Using the Same
US 9,221,788
Cited by 21 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
5-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same
US 7,635,700
Cited by 62 later US patents, top 25% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Formulations of 4-Amino-2-(2,6-Dioxopiperidine-3-YL)ISOINDOLINE-1,3-Dione
US 8,828,427
Cited by 28 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Formerly held, still cited
Notable
Ends Sep 2029 · High confidence
The most cited patent in this portfolio, cited by 317 later US patents, top 1% of utility patents granted in 2012 in our data. Protection runs to 2029.
now held by Bristol-Myers Squibb Company
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-Dione for the Treatment of Systemic Lupus Erythematosus (US 11,660,302) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 2 fees due Dec 9 to 25, 2026 · next Dec 9
- 4 fees due Jan 2 to 23, 2027 · next Jan 2
- 7 fees due Feb 4 to 28, 2027 · next Feb 4
- 3 fees due Mar 15 to 24, 2027 · next Mar 15
- 6 fees due Apr 1 to 22, 2027 · next Apr 1
- 5 fees due May 5 to 26, 2027 · next May 5
- 3 fees due Jun 3 to 29, 2027 · next Jun 3
- 6 fees due Jul 5 to 30, 2027 · next Jul 5
- 3 fees due Aug 11 to 27, 2027 · next Aug 11
- 7 fees due Sep 5 to 24, 2027 · next Sep 5
- 7 fees due Oct 2 to 23, 2027 · next Oct 2
- 2 fees due Nov 12, 2027
Recent changes
- Sep 22Assignment recorded on 1 record: Miao, Guobin and 2 others to Celgene Corporation Recorded Sep 22, 2026, executed May 21, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76111, frame 567.
- 4 of the patents on this record were granted since Aug 21, 2026
- 2 terms have ended since Aug 21, 2026
What they patent
The largest of its 140 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,465,800 | Polymorphic Forms of 3-(4-Amino-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-Dione In force · High confidence | In force | High confidence | |
| US 9,447,070 | 5-Substituted Isoindoline Compounds In force · High confidence | In force | High confidence | |
| US 9,801,868 | 5-Substituted Isoindoline Compounds In force · High confidence | In force | High confidence | |
| US 9,732,064 | 5-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 7,635,700 | 5-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 10,793,824 | Salt Formulations for the Fermentation of Marine Microorganisms held by Celgene International II SARL In force · High confidence | In force | High confidence | |
| US 7,863,451 | Processes for the Preparation of Substituted 2-(2,6-Dioxopiperidin-3-YL)-1-Oxoisoindolines In force · High confidence | In force | High confidence | |
| US 9,181,216 | 4'-O-SUBSTITUTED Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 9,920,027 | 4'-O-SUBSTITUTED Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US RE46,639 | 4'-O-SUBSTITUTED Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 291: 111 patents in force now held by others · 181 patents ended · 109 applications pending · 306 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.